The market is choppy this morning so it is difficult to read anything into the price action. I am growing slightly more constructive on the near term of the sector but that is a very low conviction view. While the sector bounced on support, I have a hard time believing that the sell off was […]
April 8 Biotech Update
It was actually a good morning for the sector with large and SMID caps doing well. While that is a good first step, we need these moves to not only stick but strengthen at the end of the day. Another fade would indicate that the selling pressure remains a headwind. The sector is in an […]
April 6 Biotech Update
I have not had a chance to follow the market last week, so I do not really have a sense how the sector is doing. It looks like it has been more of the same with weakness and large caps trudging along and unable to generate any real leadership. The sector is certainly lagging the […]
Catalyst Watch – Vol. 3, Edition 4 (4/3/15)
Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted), are subject to potential future, pre-catalyst revision and are not intended as investment recommendations. Please read our Disclaimer: (1) Catalyst Watch List: AMPE: Ampio has […]
Chimera Research Group Catalyst Summary for March 2015
At the end of each month Chimera Research Group provides you with a monthly summary of TEN notable catalysts/events that have occurred during the past month. MARCH 2015: 1) Bristol-Myers Squibb Company (NYSE:BMY) announced that the FDA approved the expanded use of Opdivo to treat patients with advanced squamous non-small cell lung cancer (NSCLC). Approval came just over two […]
BMY – Is the Technical Correction Done ?
Bristol-Myers Squibb Company (BMY) –NYSE Bristol-Myers Squibb Co. (BMY) had a wild year, up from the lows of $47.54 in mid October 2014 to reach a new 12 years high $69.20 in March, 20th 2015, getting a boost from the fastest FDA approval I ever seen. On Febreuary 27th 2015 the FDA granted Priority Review […]
March 31 Biotech Update
The sector was relatively weak yesterday and did not start this morning particular strong. I still am noticing the large cap lagging trend that has been going on for awhile. Is this simply a function of the lack of near term catalysts, increasing bearishness on the large caps, investors chasing returns lower on the capital […]
March 30 Biotech Update
It looks like we have all survived the great biotech sell off of 2015. To be honest, I am not sure this really counts as a sell off (yet). We have been spoiled by the steady march higher and while this is a nice bounce, we were also very oversold in the short term. Add […]
March 27 Biotech Update
The sector is in bounce mode. While I certainly think there is room for a rally after the sharp selling, I would not read this as an all clear. Yes, the downdraft took some of the overvalued names down pretty far but this seems too orderly and easy for it to be done. Obviously, we […]
March 25 Biotech Update
A rough start to morning for the sector with a biotech bubble article in the WSJ not helping. There was nothing new but the headline is the headline (it also had some odd numbers like CELG P/E over 50, which is much higher than the numbers I usually see when calculating CELG P/E). Of course, […]
March 24 Biotech Update
Today seems to be a slow day, so I will try and keep it short and to the point. The sector held up better than I would have thought yesterday, although it was a clear underperformer. What seemed a little odd was that it was not GILD or BIIB leading the large caps lowers but […]
March 23 Biotech Update
A weak start to the week but it is also a continuation from the weak ending of last week. Everyone is waiting for a pullback. The bulls expect a moderate pullback to consolidate the move, the bears expect a more significant move to purge a lot of the excess valuation, and the bubble callers are […]
March 20 Biotech Update
I believe there was some sort of data that came out today that had people talking. LOL. The BIIB data neatly dovetailed into biotech valuation discussion and so I want to spend time talking about both the BIIB data and valuations. I want to try and separate them as while they are clearly linked, they […]
Catalyst Watch – Vol. 3, Edition 3 (3/18/15)
Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted), are subject to potential future, pre-catalyst revision and are not intended as investment recommendations. Please read our Disclaimer: (1) Catalyst Watch List: AMPE: As mentioned, […]
March 18 Biotech Update
Some early weakness but I also suspect today is going to be fairly volatile with the Fed weighing in later this afternoon. So I am really not going to read anything into the price action this morning and even less into the price action in the sector after the announcement. Given how close people think […]
March 17 Biotech Update
The market is weak but the biotech sector is showing good strength. The large caps seem to be holding up their end of the bargain, which bodes well for this move. I do wonder when the new leg down in oil prices hits the broader market. It seems to be handling it well but if […]
Adamas Pharmaceuticals: two interesting programs for Alzheimer and Parkinsons Diseases
Adamas Pharmaceuticals, Inc. (ADMS) –Nasdaq Adamas (ADMS) is a company focused on CNS diseases, specifically Parkinson’s (PD) and Alzheimer’s Diseases (AD). It has a low market cap (~$300M), plenty of cash ($158M), low float with most of the shares (64.2%) held by insiders and institutions (link), two FDA approved products partnered with Forest/Actavis (for one […]
Adamas Pharmaceuticals – Volatility Squeeze Action
Adamas Pharmaceuticals, Inc. (ADMS) –Nasdaq Adamas pharmaceutical had its initial public offering last year April 10th, the closing of its IPO of 3 million shares at a public offering price of $16.00 per share. The shares began trading on The NASDAQ Global Market under the ticker symbol “ADMS” on April 10, 2014. Adamas had […]
March 16 Biotech Update
A good start to the week with a new all-time high in the IBB but I still want to see how the large caps perform in the afternoon. The pattern seems to be early strength followed by weakness in the afternoon but maybe this time is different. Of course, SMIDs seem to have strength early […]
March 13 Biotech Update
I know that the sector is doing well and near highs but I cannot shake the feeling that the stocks feel heavy. I do not have a better way to describe it nor anything more solid than this impression. Perhaps this is simply the wall of worry that we are going to climb. If I […]
